A rare case of poorly differentiated mixed neuroendocrine-nonneuroendocrine tumor of the caecum with long term survival: A case report
Author:
Polymeris Antonis1, Kogia Christina1, Kazakou Paraskevi2, Psachna Stavroula1, Lilis Dimitrios1, Drakou Maria1, Michalakis Konstantinos1, Ioannidis Dimitrios1
Affiliation:
1. Department of Endocrinology , Metabolism and Diabetes Mellitus/Sismanogleio-Amalia Fleming Hospital , Athens , Greece 2. Endocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine , National and Kapodistrian University of Athens , Athens , Greece
Abstract
Abstract
A 59-year-old woman presented with flushing attacks accompanied by tachycardia and hypotension, which lasted approximately 30 to 60 minutes, underwent 18 years ago a gastrointestinal tumor resection. The histologic examination revealed a poorly differentiated mixed neuroendocrine/adenocarcinoma located in the caecum with regional metastases. Postoperatively, the patient received combined chemotherapy of 5-fluorouracil with interferon for six months and since has remained asymptomatic. Her examination revealed positivity for chromogranin A (CgA) and a-Fetoprotein (aFP) (580 ng/24 h, normal range 27–94, and 10 IU/mL, normal range 0–6, respectively). Urinary 5-hydroxy indole acetic acid excretion was remarkably high (41.8 mg/24 h, normal range 2–10 mg/24 h). An abdominal Magnetic Resonance Imaging scan revealed multiple focal loci in the liver whose histological examination revealed a carcinoid tumor confirmed by an Octreoscan. Additional uptake was noted on the right shoulder and the right sternum-clavicle joint confirmed by Tc-99m MDP scan. The patient received somatostatin analogue therapy followed by long-acting release octreotide analogue therapy (30 mg/month) showing a partial improvement of relevant biomarkers. Two years later, carcinoid syndrome symptoms reappeared and due to the tumors expression of somatostatin receptors the patient received peptide receptor radionuclide therapy with 177Lu-DOTATATE that resulted in both clinical and biochemical improvements.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference28 articles.
1. Bazerbachi F, Kermanshahi TR, Monteiro C. Early precursor of mixed endocrine-exocrine tumors of the gastrointestinal tract: Histologic and molecular correlations. Ochsner J 15, 97–101, 2015. 2. Brathwaite S, Rock J, Yearsley MM, Bekaii-Saab T, Wei L, Frankel WL, Hays J, Wu C, Abdel-Misih S. Mixed adenoneuroendocrine carcinoma: An aggressive clinical entity. Ann Surg Oncol 23, 2281–2286, 2016.10.1245/s10434-016-5179-2 3. Casas F, Ferrer F, Farrus B, Casals J, Biete A. Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis. Cancer 80, 1366–7213, 1997.10.1002/(SICI)1097-0142(19971015)80:8<1366::AID-CNCR2>3.0.CO;2-D 4. de Mestier L, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, Bouche O, Cadiot G, Ruszniewski P, Couvelard A, Hammel P. Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms. Neuroendocrinology 105, 412–425, 2017.10.1159/000475527 5. Ho KJ, Herrera GA, Jones JM, Alexander CB. Small cell carcinoma of the esophagus: evidence for a unified histogenesis. Hum Pathol 15, 460–468, 1984.10.1016/S0046-8177(84)80081-7
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|